Victorium Clinical Research - Houston
Welcome,         Profile    Billing    Logout  
 6 Trials 
35 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nakhle, Samer
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed
4
152
US
Tirzepatide, LY3298176
Eli Lilly and Company
Type 2 Diabetes, Diabetes Mellitus, Type 2
10/23
10/23
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05514548 / 2022-002140-51: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Completed
2
265
Europe, Canada, US, RoW
INV-202, None applicable, Placebo
Inversago Pharma Inc., Worldwide Clinical Trials
Diabetic Kidney Disease
08/24
09/24
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Active, not recruiting
2
150
US
Enobosarm, Semaglutide, Wegovy
Veru Inc.
Muscle Loss, Obesity
12/24
04/25
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting
2
186
Canada, US
Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg
Zucara Therapeutics Inc.
Type 1 Diabetes Mellitus with Hypoglycemia
06/25
07/25
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo

Recruiting
2
120
US
Nimacimab injection, Nimacimab placebo injection, semaglutide injection
Skye Bioscience, Inc., Bird Rock Bio Sub, Inc.
Obesity
08/25
01/26
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
NCT04604093: Effect of the FreeStyle Libre 2 Flash Glucose Monitoring System on Hyperglycemia in People With T2 Diabetes

Completed
N/A
358
US
SMBG Meter, FreeStyle Libre 2 System
Abbott Diabetes Care
Diabetes Mellitus
02/23
03/23
NCT04595968: Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus

Completed
N/A
267
Europe, US
Vestal DM Active device, Lifestyle modification, Vestal DM Sham device
Neurovalens Ltd., University College Dublin, CS Lifescience, Clinical Trial Mentors
Type 2 Diabetes
08/24
08/24
PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting
N/A
1339
Europe, Canada, US
No intervention
Takeda, Takeda Development Center Americas, Inc.
Hypoparathyroidism
11/34
11/34
Doshi, Ankur
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24
Ranga, Vishweshwar
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Cone, Clancy
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
Masani, Naveed
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
HOME, NCT04526301: Home With TablO outcoMEs () Registry

Recruiting
N/A
500
US
Tablo Hemodialysis System
Outset Medical
End Stage Renal Disease
07/24
07/24
Perryman, Cinda
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
Numrungroad, Visal
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25

Download Options